Maternal Omics to Maximize Immunity

母体组学最大化免疫力

基本信息

项目摘要

Overall: Summary From the moment of fertilization to birth, the maternal immune system evolves, adapts, and supports the growth of a fetal allograft that ultimately perpetuates the human race. Immunological changes throughout a pregnancy play a key deterministic role in the success of the pregnancy. While pregnancy was historically regarded as a simple shift towards tolerance, emerging immunological data point to remarkable dynamic changes during pregnancy. The pregnancy immunome must protect the fetus from a maternal attack while at the same time it must afford the maternal-fetal dyad protection from invading pathogens. The health of the mother and the fetus requires that these two opposing immunological tasks work in concert. Thus collectively, pregnancy marks a whirlwind of immune adaptations that render the pregnant immune system a truly unique immunologic marvel. Despite our growing appreciation for these highly controlled dynamic shifts, the precise mechanisms that lead to optimal pregnancy health, profoundly impacting both mother and fetus, are incompletely understood, delaying the development of targeted therapies for this population. Capitalizing on this unique moment in vaccine history, with the introduction of several novel-vaccine platforms for SARS-CoV-2, the consortium will build a Pregnancy Immune Atlas via the application of high-density immunological profiling technologies to deeply and comprehensively dissect the overall changes that occur across pregnancy and how the immune system, as a collective, responds to in vivo perturbations with vaccines. Using both de novo vaccine induced immune responses and booster vaccination, the consortium will capture overall changes in the pregnant ImmunOME as well as shifts in the pregnant AdaptOME to fully capture the immunological mechanisms that govern the balanced growth of the fetus and battle of the maternal:fetal dyad against invading pathogens. Thus, together the Maternal ‘Omics to Maximize Immunity (MOMi) consortium seeks to build the foundational data to advance our knowledge of natural tolerance, fertility, shifts in immunity during pregnancy to better understand this evolutionary marvel required for the perpetuation of the human species.
总体:总结 从受精到出生,母体免疫系统不断进化、适应和支持 最终使人类永存的胎儿同种异体移植物的生长。整个过程中的免疫变化 妊娠对于妊娠的成功起着关键的决定性作用。虽然历史上怀孕是 新兴的免疫学数据被认为是向耐受性的简单转变,表明了显着的动态变化 怀孕期间的变化。妊娠免疫组必须保护胎儿在怀孕期间免受母体攻击 同时,它必须提供母胎二元保护,使其免受病原体的入侵。母亲的健康 胎儿需要这两种相反的免疫任务协同工作。因此,总的来说,怀孕 标志着免疫适应的旋风,使怀孕的免疫系统成为真正独特的免疫系统 奇迹。尽管我们越来越欣赏这些高度受控的动态变化,但其精确机制 导致最佳怀孕健康,深刻影响母亲和胎儿,但尚未完全了解, 推迟针对该人群的靶向治疗的开发。利用疫苗的这一独特时刻 历史上,随着针对 SARS-CoV-2 的多个新型疫苗平台的推出,该联盟将建立一个 妊娠免疫图谱通过应用高密度免疫分析技术来深入、 全面剖析怀孕期间发生的整体变化以及免疫系统如何作为 集体,用疫苗应对体内扰动。使用两种从头疫苗诱导免疫 反应和加强疫苗接种,该联盟将捕获怀孕 ImmunOME 的总体变化,如下所示: 以及怀孕的 AdaptOME 的转变,以充分捕捉控制平衡的免疫机制 胎儿的生长和母体:胎儿二人对抗入侵病原体的战斗。于是,妈妈们一起 ‘最大化免疫组学 (MOMi) 联盟致力于建立基础数据来推进我们的研究 了解自然耐受性、生育能力、怀孕期间免疫力的变化,以更好地理解这种进化 人类延续下去所需要的奇迹。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MICHAL Aviva ELOVITZ其他文献

MICHAL Aviva ELOVITZ的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MICHAL Aviva ELOVITZ', 18)}}的其他基金

Unraveling mechanisms by which cervicovaginal microbiota can promote or prevent cervical remodeling and preterm birth
揭示宫颈阴道微生物群促进或预防宫颈重塑和早产的机制
  • 批准号:
    10800388
  • 财政年份:
    2023
  • 资助金额:
    $ 235.4万
  • 项目类别:
Deciphering the Role of Vaginal Microbes in Preterm birth
解读阴道微生物在早产中的作用
  • 批准号:
    10647700
  • 财政年份:
    2023
  • 资助金额:
    $ 235.4万
  • 项目类别:
Deciphering the Role of Vaginal Microbes in Preterm birth
解读阴道微生物在早产中的作用
  • 批准号:
    10800417
  • 财政年份:
    2023
  • 资助金额:
    $ 235.4万
  • 项目类别:
Maternal Omics to Maximize Immunity
母体组学最大化免疫力
  • 批准号:
    10420106
  • 财政年份:
    2022
  • 资助金额:
    $ 235.4万
  • 项目类别:
Unraveling mechanisms by which cervicovaginal microbiota can promote or prevent cervical remodeling and preterm birth
揭示宫颈阴道微生物群促进或预防宫颈重塑和早产的机制
  • 批准号:
    10223393
  • 财政年份:
    2020
  • 资助金额:
    $ 235.4万
  • 项目类别:
Unraveling mechanisms by which cervicovaginal microbiota can promote or prevent cervical remodeling and preterm birth
揭示宫颈阴道微生物群促进或预防宫颈重塑和早产的机制
  • 批准号:
    9886482
  • 财政年份:
    2020
  • 资助金额:
    $ 235.4万
  • 项目类别:
Unraveling mechanisms by which cervicovaginal microbiota can promote or prevent cervical remodeling and preterm birth
揭示宫颈阴道微生物群促进或预防宫颈重塑和早产的机制
  • 批准号:
    10397425
  • 财政年份:
    2020
  • 资助金额:
    $ 235.4万
  • 项目类别:
Deciphering the Role of Vaginal Microbes in Preterm birth
解读阴道微生物在早产中的作用
  • 批准号:
    10026955
  • 财政年份:
    2020
  • 资助金额:
    $ 235.4万
  • 项目类别:
Deciphering the Role of Vaginal Microbes in Preterm birth
解读阴道微生物在早产中的作用
  • 批准号:
    10432076
  • 财政年份:
    2020
  • 资助金额:
    $ 235.4万
  • 项目类别:
Deciphering the Role of Vaginal Microbes in Preterm birth
解读阴道微生物在早产中的作用
  • 批准号:
    10249230
  • 财政年份:
    2020
  • 资助金额:
    $ 235.4万
  • 项目类别:

相似海外基金

Establishment of novel osteochondral allografting combined with growth factor- collagen-binding domain fusion technology
新型同种异体骨软骨移植联合生长因子-胶原蛋白结合域融合技术的建立
  • 批准号:
    26462277
  • 财政年份:
    2014
  • 资助金额:
    $ 235.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Translating PTH Therapy as an Adjuvant for Structural Allografting
将 PTH 疗法转化为结构性同种异体移植的佐剂
  • 批准号:
    8344380
  • 财政年份:
    2012
  • 资助金额:
    $ 235.4万
  • 项目类别:
Allografting for Lukemia
白血病同种异体移植
  • 批准号:
    8260361
  • 财政年份:
    2011
  • 资助金额:
    $ 235.4万
  • 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
  • 批准号:
    7878675
  • 财政年份:
    2009
  • 资助金额:
    $ 235.4万
  • 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
  • 批准号:
    7677758
  • 财政年份:
    2009
  • 资助金额:
    $ 235.4万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7466112
  • 财政年份:
    2008
  • 资助金额:
    $ 235.4万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    8010394
  • 财政年份:
    2008
  • 资助金额:
    $ 235.4万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    8208131
  • 财政年份:
    2008
  • 资助金额:
    $ 235.4万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7575273
  • 财政年份:
    2008
  • 资助金额:
    $ 235.4万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7765518
  • 财政年份:
    2008
  • 资助金额:
    $ 235.4万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了